Pelthos Therapeutics Inc.
AMEX:PTHSBiotechnology
-$0.37 today
- Market cap
- $63.32M
- Beta
- 3.13
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$15.58
Volume 0.01M
Average 0.04M
PTHS Account Payables
Amounts the company owes suppliers for goods and services received.
Pelthos Therapeutics Inc.AMEX: PTHS
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 136.1% from a year ago
Account payables stood at $6.15M at the end of Q1 FY2026, up 136.1% from a year earlier and up 105.9% from the prior quarter. Over 3 fiscal years it compounded at -0.1% a year.
Context
- Account payables amounted to 4.2% of total assets at the end of Q1 FY2026, down 281.5 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +136.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 2.99M USD
- Year-over-year change
- +57.4%
- 3-year CAGR
- -0.1%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.99M | +57.4% |
| FY2024 | 2024-12-31 | 1.9M | -58.9% |
| FY2023 | 2023-12-31 | 4.62M | +54.3% |
| FY2022 | 2022-12-31 | 2.99M | — |
Account Payables vs competitors
How PTHS compares with its peers on the latest reported figures
- PTHS's Mar 2026 account payables of $6.15M is the highest of the 4 companies compared; the peer median is $2.67M.
- Its year-over-year change of +136.1% is the lowest of 4, against a peer median of +247.7%.
- Account payables amounts to 4.2% of total assets for PTHS, versus a peer median of 3.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $6.15M | +136.1% | -0.1% | 4.2% | |
| Dec 2025 | $3.81M | +369.5% | +25.0% | 0.2% | |
| Mar 2026 | $2.67M | +212.2% | +38.7% | 8.7% | |
| Mar 2026 | $391.08K | +247.7% | +1234.3% | 3.6% | |
| Peer median (excluding PTHS) | $2.67M | +247.7% | +38.7% | 3.6% | |
Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Pelthos Therapeutics Inc.
AMEX:PTHS
Intrinsic Alpha fair value
Locked
Current Price
$16.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.